Wall Street analysts expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to announce $0.07 earnings per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.12 and the lowest estimate coming in at $0.02. Vanda Pharmaceuticals reported earnings per share of $0.20 during the same quarter last year, which would indicate a negative year over year growth rate of 65%. The company is expected to issue its next quarterly earnings report on Wednesday, November 6th.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year earnings of $0.32 per share for the current fiscal year, with EPS estimates ranging from $0.27 to $0.35. For the next financial year, analysts expect that the company will post earnings of $0.82 per share, with EPS estimates ranging from $0.20 to $1.75. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.24. The business had revenue of $59.06 million during the quarter, compared to analyst estimates of $54.19 million. Vanda Pharmaceuticals had a return on equity of 10.23% and a net margin of 13.61%. Vanda Pharmaceuticals’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.15 EPS.
In related news, CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $15.34, for a total value of $1,117,856.48. Following the sale, the chief executive officer now owns 1,276,343 shares in the company, valued at approximately $19,579,101.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.20% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. Advisor Group Inc. boosted its holdings in shares of Vanda Pharmaceuticals by 66.2% in the 4th quarter. Advisor Group Inc. now owns 2,916 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 1,161 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Vanda Pharmaceuticals by 104.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 530,705 shares of the biopharmaceutical company’s stock worth $13,867,000 after purchasing an additional 270,795 shares in the last quarter. Amalgamated Bank purchased a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth about $214,000. Geode Capital Management LLC boosted its holdings in shares of Vanda Pharmaceuticals by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 596,626 shares of the biopharmaceutical company’s stock worth $15,588,000 after purchasing an additional 6,666 shares in the last quarter. Finally, Strs Ohio boosted its holdings in shares of Vanda Pharmaceuticals by 28.4% in the 1st quarter. Strs Ohio now owns 42,500 shares of the biopharmaceutical company’s stock worth $782,000 after purchasing an additional 9,400 shares in the last quarter. Institutional investors own 99.33% of the company’s stock.
VNDA opened at $15.05 on Friday. The firm’s 50 day simple moving average is $13.85. The company has a market cap of $801.77 million, a price-to-earnings ratio of 31.35 and a beta of 0.38. Vanda Pharmaceuticals has a one year low of $11.83 and a one year high of $33.44.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Further Reading: Outstanding Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.